View ValuationCurexo 将来の成長Future 基準チェック /46Curexoは、61.1%と17.4%でそれぞれ年率61.1%で利益と収益が成長すると予測される一方、EPSはgrowで61.9%年率。主要情報61.1%収益成長率61.87%EPS成長率Consumer Retailing 収益成長25.4%収益成長率17.4%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日07 Mar 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 23Curexo Inc. announced that it expects to receive KRW 500 million in fundingCurexo Inc. announced a private placement of Series 3 Unregistered Unsecured Private Convertible Bonds of the company to raise gross proceeds of KRW 500,000,000 on April 22, 2026. The transaction involves participation from individual investor Ha Yong-chan for KRW 200,000,000, Yoon Seon-joong for KRW 200,000,000 and Yoo Jun-il for KRW 100,000,000. The Bonds are 100% convertible into 31,174 Common Shares of the company at a conversion price of KRW 16,039 and the conversion billing period will start from April 30, 2027 till March 31, 2029. The Bonds carry an interest rate of 3% and maturity interest of 4%. The Bonds have a maturity date of April 30, 2029. The transaction has been approved by Board of Directors of the company. The securities being issued in this transaction are on a hold period for 1 year. The transaction is expected to close on April 30, 2026.お知らせ • Feb 06Curexo Inc., Annual General Meeting, Mar 26, 2026Curexo Inc., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 114, taebong-ro, seocho-gu, seoul South KoreaNew Risk • Feb 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). Share price has been highly volatile over the past 3 months (13% average weekly change). High level of non-cash earnings (74% accrual ratio).お知らせ • Feb 08Curexo Inc., Annual General Meeting, Mar 26, 2025Curexo Inc., Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 114, taebong-ro, seocho-gu, seoul South KoreaNew Risk • Jan 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). High level of non-cash earnings (74% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.8% average weekly change).New Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). High level of non-cash earnings (74% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding).New Risk • Jul 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (74% accrual ratio). Minor Risk Shareholders have been diluted in the past year (5.3% increase in shares outstanding).Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • May 22CUREXO Corp. Spinal Surgery Robot, 'Cuvis-Spine' Acquires FDA (US) LicensingCUREXO Corp. announced their independently developed spinal surgery robot 'CUVIS-spine' has acquired FDA (US) licensing. This FDA (US) license, followed by Korea (2019) and Europe CE (2020) certificate is the 3rd license that they have acquired and now their product can be supplied to all countries. Currently, 2 'CUVIS-spine's are being used in Severance Hospital (Korea) and 1 has been exported to an Australian medical facility company. CUREXO also plans to expand their focus on global markets including the US and Europe. Spinal surgery robot 'CUVIS-spine' is a next-gen spinal surgery robot that guides the insertion of a pedicle screw according to the surgery plan. It uses a high precision robot arm, wireless one-step, navigation based on a real-time GPS sensor to provide precise, safe and faster surgery compared to traditional manual surgery. Also, it minimizes the filming and reduces the radiation exposure of both patients and medical staff. Both 2-dimensional filming (C-arm) and 3-dimensional filming (O-arm) are applicable with this solution which provides great expandability. With the Wireless One-step and the robot system, it allows multiple steps (Needle, K-wire, Dilation, Tapping) of traditional manual surgery to be performed with one surgery tool and it reduces surgery duration greatly. It allows Minimally Invasive Surgery (MIS) which means that the patient's recovery time will be quicker compared to manual surgery.お知らせ • May 21Curexo Inc. announced that it has received KRW 15 billion in funding from Korea Investment & Securities Co., Ltd., Investment ArmOn May 20, 2021, Curexo Inc. (KOSDAQ:A060280) closed the transaction.お知らせ • May 14Curexo Inc. announced that it expects to receive KRW 15 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm and another investorCurexo Inc. (KOSDAQ:A060280) announced a private placement of round 2 non-guaranteed private equity convertible bonds for gross proceeds of KRW 15,000,000,000 on May 13, 2021. The bonds do not carry any coupon. The bonds will mature on May 20, 2026. The transaction will include participation from new investors Korea Investment & Securities Co., Ltd., Investment Arm and Global Robot Healthcare New Technology Business Fund. The bonds are 100% convertible into 1,434,165 common shares at a price of KRW 10,459 per share. The conversion period of the bonds is from May 20, 2022 to April 20, 2026. The transaction is expected to close on May 20, 2021. The transaction has been approved by the board of directors of the company.お知らせ • Feb 10Curexo Inc., Annual General Meeting, Mar 24, 2021Curexo Inc., Annual General Meeting, Mar 24, 2021, at 09:00 Korea Standard Time.Is New 90 Day High Low • Jan 05New 90-day high: ₩7,170The company is up 14% from its price of ₩6,310 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is up 9.0% over the same period.業績と収益の成長予測KOSDAQ:A060280 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202797,7008,100N/AN/A112/31/202688,7006,100N/AN/A13/31/202670,9182,137-7,017-4,820N/A12/31/202574,5322,771-13,772-11,258N/A9/30/202568,569-4,355-10,575-7,109N/A6/30/202564,580-6,744-8,279-3,300N/A3/31/202561,299-7,295-2,968530N/A12/31/202455,531-8,7584653,850N/A9/30/201627,848-16,147N/A-41,183N/A6/30/201627,540-12,602N/A-28,787N/A3/31/201627,957-10,978N/A-20,201N/A12/31/201527,530-9,402N/A-19,789N/A9/30/201528,708-9,238N/A-17,183N/A6/30/201527,426-11,394N/A-25,270N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A060280の予測収益成長率 (年間61.1% ) は 貯蓄率 ( 3.1% ) を上回っています。収益対市場: A060280の収益 ( 61.1% ) はKR市場 ( 31.2% ) よりも速いペースで成長すると予測されています。高成長収益: A060280の収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: A060280の収益 ( 17.4% ) KR市場 ( 15.5% ) よりも速いペースで成長すると予測されています。高い収益成長: A060280の収益 ( 17.4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A060280の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YConsumer-retailing 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 02:14終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Curexo Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Song-hyup HanDaishin Securities Co. Ltd.Kyeongkeun KangNH Investment & Securities Co., Ltd.Jin-Hyoeng ParkYuanta Securities Korea Co., Ltd.
お知らせ • Apr 23Curexo Inc. announced that it expects to receive KRW 500 million in fundingCurexo Inc. announced a private placement of Series 3 Unregistered Unsecured Private Convertible Bonds of the company to raise gross proceeds of KRW 500,000,000 on April 22, 2026. The transaction involves participation from individual investor Ha Yong-chan for KRW 200,000,000, Yoon Seon-joong for KRW 200,000,000 and Yoo Jun-il for KRW 100,000,000. The Bonds are 100% convertible into 31,174 Common Shares of the company at a conversion price of KRW 16,039 and the conversion billing period will start from April 30, 2027 till March 31, 2029. The Bonds carry an interest rate of 3% and maturity interest of 4%. The Bonds have a maturity date of April 30, 2029. The transaction has been approved by Board of Directors of the company. The securities being issued in this transaction are on a hold period for 1 year. The transaction is expected to close on April 30, 2026.
お知らせ • Feb 06Curexo Inc., Annual General Meeting, Mar 26, 2026Curexo Inc., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 114, taebong-ro, seocho-gu, seoul South Korea
New Risk • Feb 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). Share price has been highly volatile over the past 3 months (13% average weekly change). High level of non-cash earnings (74% accrual ratio).
お知らせ • Feb 08Curexo Inc., Annual General Meeting, Mar 26, 2025Curexo Inc., Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 114, taebong-ro, seocho-gu, seoul South Korea
New Risk • Jan 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). High level of non-cash earnings (74% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.8% average weekly change).
New Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). High level of non-cash earnings (74% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding).
New Risk • Jul 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (74% accrual ratio). Minor Risk Shareholders have been diluted in the past year (5.3% increase in shares outstanding).
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • May 22CUREXO Corp. Spinal Surgery Robot, 'Cuvis-Spine' Acquires FDA (US) LicensingCUREXO Corp. announced their independently developed spinal surgery robot 'CUVIS-spine' has acquired FDA (US) licensing. This FDA (US) license, followed by Korea (2019) and Europe CE (2020) certificate is the 3rd license that they have acquired and now their product can be supplied to all countries. Currently, 2 'CUVIS-spine's are being used in Severance Hospital (Korea) and 1 has been exported to an Australian medical facility company. CUREXO also plans to expand their focus on global markets including the US and Europe. Spinal surgery robot 'CUVIS-spine' is a next-gen spinal surgery robot that guides the insertion of a pedicle screw according to the surgery plan. It uses a high precision robot arm, wireless one-step, navigation based on a real-time GPS sensor to provide precise, safe and faster surgery compared to traditional manual surgery. Also, it minimizes the filming and reduces the radiation exposure of both patients and medical staff. Both 2-dimensional filming (C-arm) and 3-dimensional filming (O-arm) are applicable with this solution which provides great expandability. With the Wireless One-step and the robot system, it allows multiple steps (Needle, K-wire, Dilation, Tapping) of traditional manual surgery to be performed with one surgery tool and it reduces surgery duration greatly. It allows Minimally Invasive Surgery (MIS) which means that the patient's recovery time will be quicker compared to manual surgery.
お知らせ • May 21Curexo Inc. announced that it has received KRW 15 billion in funding from Korea Investment & Securities Co., Ltd., Investment ArmOn May 20, 2021, Curexo Inc. (KOSDAQ:A060280) closed the transaction.
お知らせ • May 14Curexo Inc. announced that it expects to receive KRW 15 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm and another investorCurexo Inc. (KOSDAQ:A060280) announced a private placement of round 2 non-guaranteed private equity convertible bonds for gross proceeds of KRW 15,000,000,000 on May 13, 2021. The bonds do not carry any coupon. The bonds will mature on May 20, 2026. The transaction will include participation from new investors Korea Investment & Securities Co., Ltd., Investment Arm and Global Robot Healthcare New Technology Business Fund. The bonds are 100% convertible into 1,434,165 common shares at a price of KRW 10,459 per share. The conversion period of the bonds is from May 20, 2022 to April 20, 2026. The transaction is expected to close on May 20, 2021. The transaction has been approved by the board of directors of the company.
お知らせ • Feb 10Curexo Inc., Annual General Meeting, Mar 24, 2021Curexo Inc., Annual General Meeting, Mar 24, 2021, at 09:00 Korea Standard Time.
Is New 90 Day High Low • Jan 05New 90-day high: ₩7,170The company is up 14% from its price of ₩6,310 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is up 9.0% over the same period.